PF-Atlas › Clinical Trials › NCT02579603

Safety, Tolerability and PK of Nintedanib in Combination With Pirfenidone in IPF

Nintedanib · Phase 4

Registry ID
NCT02579603
Phase
Phase 4
Status
Completed
Drug / intervention
Nintedanib
Sponsor
Boehringer Ingelheim
Start
2015-10-16

About this trial

Nintedanib is evaluated in NCT02579603, a Phase 4 idiopathic pulmonary fibrosis study sponsored by Boehringer Ingelheim. Current status: Completed.

View NCT02579603 on ClinicalTrials.gov →

Explore related

All Nintedanib trialsAll IPF trials

Related trials

nintedanib — NCT02606877Nintedanib — NCT02598193Nintedanib — NCT02597933Nintedanib — NCT02999178Nintedanib — NCT02607722Nintedanib — NCT05799755
Medical disclaimer. This page summarizes public trial data for NCT02579603 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.